First Colombia Development Corp. Appoints Recognized Global Health Leader Dr. Delon Human to Board of Directors
SAUSALITO, Calif., August 14, 2019 (Newswire.com) - First Colombia Development Corp. (“First Colombia”) (OTC:FCOL) announces the appointment of Dr. Delon Human to its board of directors. Dr. Human is a recognized global health leader, published author, lecturer and healthcare consultant specializing in global health strategy, corporate and product transformation, harm reduction, access to healthcare and health communication.
“I am delighted Dr. Human accepted the invitation to serve on our board,” said Christopher Hansen, CEO and president of First Colombia. “His insights, based on decades of experience working worldwide within the healthcare services, pharmaceuticals, medical devices and food and beverage arenas, should be extremely valuable to the Company in working with regulators, distributors, healthcare provider organizations and end-user consumer groups. Dr. Human’s skill in articulating clear messaging to diverse audiences will be especially helpful, as education will be a key component of our growth strategy in this expanding industry in which regulators, doctors and patients alike continue the process of learning about cannabis-based options for enhancing wellness.”
“I look forward to helping refine strategy and support the growth of First Colombia in this rapidly evolving U.S. medicinal cannabis industry,” Dr. Human stated. “My experience in regulatory affairs, product development, science and consumer insights with corporate, governmental and non-profit agencies will allow me to contribute meaningfully to First Colombia’s expansion, in particular, to develop innovative ways to advance provider and consumer acceptance of science-based new practices and products.”
Additionally, Kenneth Lord has resigned from the board of directors. The Company expresses appreciation for Mr. Lord’s contributions during his tenure as a director.
About Dr. Delon Human
Dr. Delon Human, M.B.Ch.B., M.Prax.Med, MFGP, DCH, MBA is currently Global Head of Health and Innovation for PharmaCielo Ltd. and its Medical and Scientific Advisory Board Chair, and served on the board of directors from 2016 to May 2019. He is also president of Health Diplomats, a specialized health, nutrition and wellness consulting group operating worldwide with clients including Fortune 500 companies, foundations, governments and NGOs such as the World Medical Association, World Dental Federation and the International Food and Beverage Alliance (IFBA).
He has acted as adviser to the WHO Director-General and to UN Secretary-General Ban Ki Moon. Until 2014, he served as Secretary-General and Special Envoy to WHO / UN of the International Food and Beverage Alliance. For eight years, Dr. Human was Secretary-General of the World Medical Association (WMA) where he worked closely with the American Medical Association, WHO and FDA leadership involved in research ethics. He was instrumental in the establishment of the World Health Professions Alliance. In 2006, he was elected Secretary-General of the Africa Medical Association (AfMA). He is a fellow of the Russian and Romanian Academies of Medical Sciences.
Dr. Human was a clinician for two decades, part of the pediatric endocrinology research unit at the John Radcliffe Hospital and was involved in the establishment of several medical centers, a hospital and an emergency clinic in South Africa. Concurrently, he established a healthcare insurance company, Human Health Care, which provided strategic planning, medical audits and consumer care services to around 250,000 insured clients of several health funds. Dr. Human qualified as a physician in South Africa and completed his postgraduate studies in family medicine and child health in South Africa and Oxford, England. His business studies (MBA) were completed at the Edinburgh Business School.
This press release is not an offer of securities, or a solicitation for purchase, subscription or sale of securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.
For more information:
+1 (415) 729-1720
This press release message may contain forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or "recurring" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company's products, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this email message. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation.
While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve First Colombia of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against First Colombia. Enforcement of federal laws in the United States remains a significant risk to the business of First Colombia and any proceedings brought against First Colombia thereunder may adversely affect the Company’s operations and financial performance.
Source: First Colombia Development Corp.